Tag: Nivolumab
Combination of Brentuximab Vedotin + Nivolumab Shows 90% Objective Response Rate...
The first reported data from an ongoing phase I/II clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with nivolumab (Opdivo; Bristol-Myers Squibb...
Collaboration to Explore the Safety and Efficacy of Combining Rova-T +...
A new Phase I/II clinical program in which Bristol-Myers Squibb collaborates with AbbVie will evaluate the safety, tolerability and efficacy of the investigational biomarker-specific...
Comparison of Three Different PD-L1 Diagnostic Tests Shows a High Degree of...
Three commercially available diagnostic tests were similarly effective in measuring PD-L1 protein expression on non-small cell lung cancer (NSCLC) tumor samples, indicating that health...
Brentuximab Vedotin Identified as Potentially Transformational in Hodgkin’s lymphoma Treament
Earlier this month, during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held in Orlando, Florida from December 5–8,...
